List of Excipients in Branded Drug LEADER ARTHRITIS PAIN RELIEVER

Generic Drugs Containing LEADER ARTHRITIS PAIN RELIEVER

Company	Ingredient	NDC	Excipient
Cardinal Health	acetaminophen	37205-034	CELLULOSE, MICROCRYSTALLINE
Cardinal Health	acetaminophen	37205-034	CROSCARMELLOSE SODIUM
Cardinal Health	acetaminophen	37205-034	HYPROMELLOSES

What are the Most Frequently-Used Excipients in LEADER ARTHRITIS PAIN RELIEVER?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	HYPROMELLOSES

Leader Arthritis Pain Reliever: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 7, 2026

Leader Arthritis Pain Reliever is an over-the-counter extended-release acetaminophen product positioned for arthritis pain. Its commercial value is driven less by active-ingredient exclusivity and more by dosage-form execution, private-label pricing, retail distribution, packaging, and regulatory compliance. The product is generally understood to contain 650 mg acetaminophen per extended-release caplet, with dosing designed around 8-hour intervals.[1]

The main commercial opportunities are differentiated excipient systems, easier-to-swallow dosage forms, senior-focused packaging, retailer-exclusive presentations, and manufacturing improvements that reduce cost without changing the approved product profile.

What is Leader Arthritis Pain Reliever?

Leader Arthritis Pain Reliever is an OTC analgesic and antipyretic containing extended-release acetaminophen. The product is marketed under the Leader private-label brand rather than as a research-based prescription medicine.

Attribute	Product profile
Brand	Leader Arthritis Pain Reliever
Active ingredient	Acetaminophen
Strength	Typically 650 mg per extended-release caplet
Therapeutic category	OTC pain reliever and fever reducer
Primary indication	Temporary relief of minor arthritis pain
Dosage form	Extended-release caplet
Administration interval	Generally every 8 hours
Regulatory pathway	OTC drug monograph or monograph-aligned private-label product
Likely commercial channel	Pharmacies, wholesale distribution, independent retailers, and private-label programs
Orange Book status	Generally not an Orange Book-listed prescription product

Acetaminophen is regulated as an OTC analgesic and antipyretic under the FDA’s nonprescription drug framework. The applicable monograph provisions address active ingredient, labeling, dosage, and safety requirements rather than granting market exclusivity to a particular retailer or manufacturer.[2]

What excipients are likely used in Leader Arthritis Pain Reliever?

The exact inactive-ingredient composition should be taken from the current package label and FDA listing for the marketed lot. Extended-release acetaminophen caplets commonly use a matrix or coated-tablet architecture containing excipients from the following functional classes:

Excipient function	Common candidates	Commercial purpose
Matrix former	Hypromellose	Controls acetaminophen release
Binder	Povidone, pregelatinized starch	Improves granule and tablet cohesion
Disintegrant	Sodium starch glycolate or crospovidone	Controls processing and residual release behavior
Lubricant	Magnesium stearate or stearic acid	Supports compression and ejection
Filler	Cellulose derivatives, starch, or dibasic calcium phosphate	Adjusts tablet weight and mechanical properties
Coating	Hypromellose, polyethylene glycol, pigments	Improves swallowing, appearance, and moisture protection
Glidant	Colloidal silicon dioxide	Improves powder flow
Opacifier or colorant	Titanium dioxide or permitted color additives	Controls appearance and product identification

The critical excipient is the release-controlling polymer. In an extended-release acetaminophen product, polymer grade, viscosity, concentration, particle size, compression force, tablet hardness, coating weight, and dissolution conditions can materially affect release performance.

A formulation that uses common excipients can still have meaningful manufacturing know-how. The defensible asset may reside in process parameters, validated dissolution methods, supplier qualification, and scale-up controls rather than in a narrow composition patent.

What excipient strategy best supports commercial growth?

The strongest strategy is to preserve monograph compliance while creating manufacturing and user-experience advantages that do not require a new drug approval.

1. Optimize the extended-release matrix

A hydrophilic hypromellose matrix is a practical platform for 650 mg acetaminophen. Development priorities include:

• Consistent release through the full dosing interval.
• Low tablet weight relative to active load.
• Adequate hardness without excessive compression.
• Low friability during bottle filling and transport.
• Reduced risk of dose dumping after common food and beverage exposure.
• Stable dissolution after long-term storage.

The formulation should be evaluated across polymer viscosity grades, polymer concentration, granulation method, compression force, and tablet porosity. A lower-cost polymer system may be commercially attractive if it maintains dissolution equivalence and manufacturing robustness.

2. Develop a senior-friendly dosage form

The core target population is older adults with arthritis pain. They may have dysphagia, reduced grip strength, impaired vision, and complex medication regimens.

Commercially relevant options include:

• Smaller-caplet geometry through higher-density excipient selection.
• A smooth, low-friction film coat.
• High-contrast imprinting.
• Easy-open but child-resistant packaging.
• Unit-dose blister packs with large-print labeling.
• Calendarized dosing cards.
• Bottles with improved closure ergonomics.

A smaller tablet or easier-opening package can support retailer differentiation without changing the active ingredient. Any change to tablet size, coating, scoring, or release characteristics requires comparative quality and stability work.

3. Explore alternative extended-release technologies

A conventional matrix tablet is likely to remain the lowest-cost platform, but other technologies may create licensing or product-line opportunities:

Technology	Potential benefit	Main barrier
Hydrophilic matrix	Low cost and scalable	Release sensitivity to process variables
Film-coated matrix	Improved swallowing and moisture protection	Coating uniformity and added cost
Multiparticulate beads	More flexible release control	Higher manufacturing complexity
Bilayer tablet	Immediate plus extended release	More difficult compression and validation
Osmotic system	Highly controlled release	Greater cost and possible patent exposure
Liquid or powder formulation	Easier administration	More difficult sustained-release control

For a private-label OTC product, the commercial case generally favors a robust matrix tablet unless the alternative dosage form creates a clear retail or adherence advantage.

What patents protect Leader Arthritis Pain Reliever?

No broad patent exclusivity should be assumed for Leader Arthritis Pain Reliever as a private-label OTC acetaminophen product. Acetaminophen itself is an old active ingredient, and the product is not generally treated as a prescription NDA product with a conventional Orange Book patent estate.

Potentially relevant rights can still exist in four areas:

1. Extended-release formulation patents. These may cover polymer combinations, release profiles, multiparticulates, or manufacturing methods.
2. Dosage-form patents. These may cover caplet geometry, coating systems, layered tablets, or modified-release structures.
3. Packaging patents. Child-resistant, senior-friendly, unit-dose, or adherence-oriented packaging may be protected.
4. Manufacturing know-how. Granulation conditions, compression parameters, coating processes, and dissolution controls may be confidential rather than patented.

The principal freedom-to-operate risk is therefore formulation and process patent review, not acetaminophen composition ownership. Relevant searches should cover U.S. patents and applications assigned to the product manufacturer, contract manufacturer, acetaminophen developers, and companies commercializing 8-hour arthritis formulations.

When does Leader Arthritis Pain Reliever lose exclusivity?

Leader Arthritis Pain Reliever does not have a conventional patent-expiration date comparable to a patented prescription drug. OTC monograph products generally rely on compliance with FDA requirements rather than product-specific market exclusivity.

The commercial protection period is instead determined by:

• Retailer or wholesaler contracts.
• Private-label supply agreements.
• Manufacturer capacity.
• Product quality and recall history.
• Brand placement and shelf access.
• Packaging differentiation.
• Cost of goods.
• Formulation and process know-how.
• Any enforceable third-party patents covering the specific extended-release design.

Because acetaminophen is widely available, competitive entry can occur through other OTC monograph-compliant products without a Paragraph IV challenge directed at Leader itself.

Are there Paragraph IV challenges to Leader Arthritis Pain Reliever?

A conventional Paragraph IV challenge is unlikely to apply to Leader Arthritis Pain Reliever because it is generally an OTC private-label product rather than a patented prescription drug listed in the Orange Book.

Paragraph IV litigation is associated with abbreviated new drug applications that certify a listed patent is invalid, unenforceable, or not infringed. A competing manufacturer seeking to market an equivalent OTC acetaminophen product would more commonly rely on the applicable OTC monograph, a monograph order process, or another FDA-recognized pathway, depending on the product and formulation.[3]

Patent litigation remains possible if a competitor’s extended-release technology allegedly infringes a formulation or process patent. That dispute would concern the technology, not an Orange Book patent challenge to the Leader brand.

What is the Orange Book status of Leader Arthritis Pain Reliever?

Leader Arthritis Pain Reliever is generally outside the principal Orange Book framework because it is an OTC product rather than a prescription drug approved under a conventional NDA. The Orange Book identifies approved drug products and certain patent and exclusivity information for applicable prescription and other listed products.[4]

The absence of an Orange Book listing does not eliminate all intellectual-property risk. It means that market entry and patent disputes must be analyzed through the product’s regulatory pathway, formulation patents, manufacturing rights, trademarks, and contractual arrangements.

What FDA regulatory issues affect the product?

The principal FDA risks are labeling, dose control, acetaminophen safety, dissolution performance, and manufacturing quality.

FDA-required consumer warnings for acetaminophen products address severe liver damage risks associated with overdose, use with other acetaminophen-containing medicines, and alcohol consumption. The product must also carry directions and warnings consistent with its monograph status and labeling requirements.[2]

Key quality controls include:

• Assay and content uniformity.
• Extended-release dissolution.
• Impurity and degradation-product control.
• Stability under labeled storage conditions.
• Tablet hardness and friability.
• Packaging integrity.
• Accurate Drug Facts labeling.
• Controls against mix-ups with immediate-release acetaminophen products.

A reformulation that changes release behavior, dose strength, route, or labeling may trigger a different regulatory analysis. Excipient substitutions that are technically minor can still require comparative dissolution, stability, and manufacturing validation.

What commercial opportunities exist for Leader Arthritis Pain Reliever?

Retailer-exclusive product architecture

Leader can compete through retailer-specific package counts, bottle sizes, blister formats, and price points. Private-label economics improve when the same validated formulation supports multiple packaging configurations.

Senior-care and institutional channels

Long-term-care facilities, assisted-living providers, and home-health distributors may value unit-dose packaging, large-print instructions, tamper evidence, and medication-administration compatibility.

Premium excipient positioning

A premium variant could emphasize:

• Easier swallowing.
• Reduced tablet size.
• Dye-free presentation.
• Gluten-free or allergen-conscious formulation, where substantiated.
• Sodium-conscious excipient selection.
• Moisture-protective packaging.
• Calendar blister compliance packaging.

These attributes must be supported by formulation records, supplier documentation, and accurate labeling. They should not imply clinical superiority unless supported by appropriate evidence.

Manufacturing and supply-chain savings

The largest near-term opportunity may be cost reduction through:

• Direct compression where feasible.
• Higher-yield granulation.
• Reduced coating weight.
• Dual-source qualification for polymers and lubricants.
• Improved acetaminophen particle-size control.
• Lower scrap rates.
• Integrated packaging lines.
• Longer supplier contracts for high-volume excipients.

Because the active ingredient is inexpensive and widely available, conversion cost, packaging, freight, quality failures, and retailer terms can have a larger impact on margin than API cost alone.

How does Leader compare with branded arthritis pain products?

Factor	Leader Arthritis Pain Reliever	Branded extended-release acetaminophen
Active ingredient	Acetaminophen	Usually acetaminophen
Primary differentiation	Price, distribution, packaging	Brand recognition and marketing
Patent value	Usually limited at brand level	May include legacy formulation or trademark assets
Regulatory pathway	OTC monograph-oriented	OTC monograph or legacy product-specific pathway
Consumer trust	Retailer brand dependent	National brand dependent
Margin strategy	Low cost and high volume	Premium pricing and brand investment
Innovation focus	Packaging, excipients, supply chain	Product extensions and brand architecture

Leader’s competitive advantage is likely to come from lower retail pricing and channel access. A differentiated excipient system matters only if it improves manufacturability, patient usability, stability, or packaging economics.

What generic entry risks exist for Leader Arthritis Pain Reliever?

Generic and private-label entry risk is high because acetaminophen is mature, widely supplied, and available in multiple OTC presentations. The principal barriers are operational:

• Qualification of an extended-release formulation.
• Reliable dissolution performance.
• FDA-compliant labeling.
• Retailer authorization.
• Contract manufacturing capacity.
• Child-resistant packaging.
• Product liability controls.
• Recall readiness.

A competitor can enter with a similar acetaminophen extended-release product without waiting for Leader patent expiry if the competitor meets the applicable regulatory requirements and avoids enforceable formulation or process rights.

What licensing deals could support the product?

Licensing opportunities are most relevant to technology rather than acetaminophen. Potential targets include:

• Extended-release polymer systems.
• Multiparticulate delivery platforms.
• Low-force compression technology.
• Coating systems that improve swallowability.
• Senior-friendly closure designs.
• Unit-dose adherence packaging.
• Contract manufacturing arrangements with validated acetaminophen platforms.

A license is commercially justified only when it provides a measurable advantage over an internally developed matrix tablet. For a high-volume OTC product, royalty-bearing technology can erode margins unless it reduces manufacturing cost, improves regulatory defensibility, or enables a premium product line.

How strong is the patent estate for Leader Arthritis Pain Reliever?

The estate is likely weak at the brand and active-ingredient levels, with potential strength concentrated in confidential manufacturing controls and any narrow extended-release technology used by the manufacturer.

IP category	Expected strength
Acetaminophen molecule	Very weak or expired
Brand name and trade dress	Moderate trademark value
Extended-release composition	Depends on third-party and manufacturer patents
Manufacturing process	Potentially strong as know-how
Packaging	Potentially protectable but narrow
OTC regulatory exclusivity	Limited compared with prescription products
Retail distribution	Commercially important but contract-based

A practical diligence program should identify the actual manufacturer, inspect the current DailyMed or product label, map the excipient composition, search formulation and process patents, and review supply and private-label agreements. The highest-value rights may not appear in public patent databases.

What geographic coverage applies?

The U.S. product’s regulatory status does not automatically support marketing in Canada, the European Union, or other jurisdictions. Each market has separate requirements for:

• Acetaminophen dose limits.
• Modified-release claims.
• OTC classification.
• Label language.
• Excipient acceptability.
• Child-resistant packaging.
• Pharmacovigilance.
• Product registration.

A single global excipient platform can reduce development cost, but the formulation and labeling may need market-specific changes. Europe and Canada may apply different expectations to modified-release dissolution and nonprescription analgesic warnings.

Key Takeaways

• Leader Arthritis Pain Reliever is an OTC extended-release acetaminophen product, generally positioned at 650 mg per caplet.
• Its commercial protection does not depend on a conventional Orange Book patent estate.
• The most relevant technical asset is the extended-release excipient and manufacturing system.
• Hypromellose-based matrix technology is likely to offer the best balance of cost, scalability, and regulatory practicality.
• Senior-friendly packaging, smaller caplets, unit-dose formats, and improved labeling are commercially attractive differentiation paths.
• Paragraph IV litigation is generally not the expected entry mechanism for competing OTC monograph products.
• Generic and private-label entry risk is high because acetaminophen is mature and widely available.
• Manufacturing know-how, supply contracts, retail access, and quality systems may be more valuable than composition patents.
• Licensing is most relevant to modified-release platforms, packaging systems, and validated contract-manufacturing capacity.
• Any excipient change requires review of dissolution, stability, labeling, and regulatory impact.

FAQs

Can Leader Arthritis Pain Reliever be reformulated with a different polymer?

Yes. A polymer substitution may be feasible, but the revised product must preserve the required extended-release performance, stability, content uniformity, and labeling profile. The change should be supported by comparative dissolution and process-validation data.

Does acetaminophen extended-release technology create a separate patent barrier?

It can. A specific extended-release matrix, multiparticulate system, coating, or manufacturing process may be covered by a patent even though acetaminophen itself is unpatented. The scope and remaining term of those rights must be reviewed independently.

Is a liquid version of Leader Arthritis Pain Reliever commercially attractive?

A liquid version could address swallowing limitations, but extended-release liquid acetaminophen is more difficult to formulate, preserve, dose accurately, and package. The opportunity is stronger for pediatric or dysphagia-focused products than for a direct private-label replacement.

Can Leader make a sodium-free or dye-free arthritis formulation?

Potentially. The excipient system can be redesigned to remove selected colorants or sodium-containing ingredients, subject to stability, processing, labeling, and substantiation requirements. The claim must match the finished product composition.

What is the largest commercial risk for this product?

The largest risk is commoditization. Competing OTC acetaminophen products can match the active ingredient and dosage form, leaving price, retailer access, packaging, supply reliability, and product quality as the main competitive variables.

References

1. DailyMed. (n.d.). Leader Arthritis Pain Reliever acetaminophen extended-release tablet label. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2023). 21 C.F.R. § 343.50: Labeling of acetaminophen-containing products.
3. U.S. Food and Drug Administration. (2024). Over-the-counter monograph drug products.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.